This may be related to gender-related pharmacokinetic differences (lower clearance of GLP-1RA in females) 41 and postmenopausal changes in gastrointestinal motility 42
Bhutta ZA, Brown KH, Gardner JM, et al
Mol Cell Neurosci (2016) 70:6875
Accessed 24 Dec 2021
The safety disclosures published on CareBareRX's own website are worth reading in full before any enrollment decision
Lilly will continue to pursue legal remedies against those who falsely claim their products are Mounjaro, Zepbound, or FDA-approved tirzepatide, including certain med-spas, wellness centers, online retailers, and compounding pharmacies. Simply put, the Big Pharma lobby is strong, the lawyers are ready and waiting, and were talking about the most commercialize-able drug in history